Ugur Sahin Biography and Net Worth

CEO of BioNTech

Prof. Ugur Sahin, M.D., Co-Founder and CEO of BioNTech, is a physician, immunologist and leader in the development of novel approaches to fight cancer and infectious diseases. Sahin is one of the world’s foremost experts on messenger ribonucleic acid (mRNA) medicines. He has pioneered several fundamental breakthroughs enabling the development of mRNA vaccines and other types of immunotherapies. The high-profile scientific publication Nature Biotechnology repeatedly listed him as one of the top 20 translational researchers worlwide.

Sahin initiated and oversaw “Project Lightspeed,” the historic development of the first mRNA vaccine for COVID-19, moving from lab and clinical testing to conditional approval within an unprecedented 11-month period. He also leads BioNTech’s research and development of neoantigen-specific as well as non-neoantigen specific mRNA cancer vaccines which can be individually tailored and produced on demand according to the profile of non-synonymous mutations identified by next-generation sequencing in patients’ tumors. Ugur Sahin is co-inventor of more than 500 filed patents applications and patents. Sahin’s academic credentials include serving as a Full Professor in Translational Oncology & Immunology at Johannes Gutenberg University in Mainz, Germany, where he supervised more than 50 PhD students. He also holds the role of Chairman of the Scientific Management Board of the Helmholtz Institute for Translational Oncology (HI-TRON). Based on his contributions to scientific discovery, Prof. Sahin has received numerous awards and recognitions, including the German Sustainability Award, the Mustafa Prize, and the German Cancer Award. He is married to Prof. Özlem Türeci.

What is Ugur Sahin's net worth?: The estimated net worth of Ugur Sahin is at least $73.08 million as of September 8th, 2026. Mr. Sahin owns 744,709 shares of BioNTech stock worth more than $73,078,294 as of September 10th. This net worth approximation does not reflect any other assets that Mr. Sahin may own. Learn More about Ugur Sahin's net worth.
How do I contact Ugur Sahin?: The corporate mailing address for Mr. Sahin and other BioNTech executives is An der Goldgrube 12, Mainz, RP, 55131. BioNTech can also be reached via phone at 49-61-31908-40 and via email at [email protected]. Learn More on Ugur Sahin's contact information.
Has Ugur Sahin been buying or selling shares of BioNTech?: During the past quarter, Ugur Sahin has sold $15,079,610.00 in shares of BioNTech stock. Most recently, Ugur Sahin sold 36,000 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $97.78, for a transaction totalling $3,520,080.00. Following the completion of the sale, the chief executive officer now directly owns 708,709 shares of the company's stock, valued at $69,297,566.02. Learn More on Ugur Sahin's trading history.
Are insiders buying or selling shares of BioNTech?: During the last year, insiders at the sold shares 5 times. They sold a total of 199,500 shares worth more than $20,607,610.00. The most recent insider tranaction occured on September, 9th when CEO Ugur Sahin sold 36,000 shares worth more than $3,520,080.00. Insiders at BioNTech own 19.2% of the company. Learn More about insider trades at BioNTech.
Information on this page was last updated on 9/9/2026.

Ugur Sahin Insider Trading History at BioNTech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2026	Sell	36,000	$97.78	$3,520,080.00	708,709
9/8/2026	Sell	37,000	$99.20	$3,670,400.00	744,709
9/4/2026	Sell	31,500	$103.52	$3,260,880.00	781,709
9/3/2026	Sell	45,000	$102.85	$4,628,250.00	813,209

Ugur Sahin Buying and Selling Activity at BioNTech

BioNTech Company Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Today's Range

Now: $98.13

$96.87

$98.64

50 Day Range

MA: $97.02

$89.33

$116.57

2 Week Range

Now: $98.13

$79.52

$124.00

Volume

706,871 shs

Average Volume

1,683,267 shs

Market Capitalization

$24.82 billion

P/E Ratio

N/A

Dividend Yield